EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis

Qianqian Pang, Xuan Qi, Yue Chi, Ruizhi Jiajue, Li Zhang, Lijia Cui, Ou Wang iD, Mei Li iD, Xiaoping Xing, Yan Jiang iD, Yiyi Gong iD, Weibo Xia iD

The Journal of Clinical Endocrinology & Metabolism · 15.07.2025 · 110 (8) · e2591-e2604

DOI: 10.1210/clinem/dgae737 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 28.11.2024. Verfasst von Qianqian Pang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory for Complex, Severe and Rare Diseas…. Hauptthemen laut MEDLINE: Metabolomics, Osteoarthropathy, Primary Hypertrophic, Oxylipins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key R&D Program of China, Beijing Municipal Natural Science Foundation, National Natural Science Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Primary hypertrophic osteoarthropathy (PHO) is a rare genetic disorder characterized by skeletal and skin abnormalities. Genetic defects in prostaglandin E2 (PGE2) metabolism are known to cause PHO. However, the global impact and clinical significance of eicosanoids and oxylipins beyond PGE2 remain to be elucidated.

Objective

This study aimed to investigate oxylipin networks in PHO, including the 2 subtypes, PHOAR1 and PHOAR2, and examine their associations with clinical characteristics.

Methods

We conducted a targeted metabolomic study involving 16 patients with PHO and 16 age- and sex-matched healthy controls. Serum samples were collected at the time of diagnosis. Metabolites were quantified using ultra-high–performance liquid chromatography-tandem mass spectrometry.

Results

Laboratory analyses confirmed elevated levels of PGE2 in patients with PHO, consistent with the established pathogenesis. About 60 oxidized lipid metabolites were identified, with 19 differentially expressed in PHO. Besides the COX/PGE2 pathway, the lipoxygenase-mediated pathway was also involved in PHO. The metabolites 5-OxoETE, 15-OxoETE, 8S,15S-DiHETE, PGE2, 11β-PGE2, PGB2, LTB4, and LTE4 were significantly altered. Correlation analyses revealed associations between oxylipin metabolites and clinical features, including bone microarchitecture. Notably, the study highlighted differences in the oxylipin metabolite profiles between patients with PHOAR1 and patients with PHOAR2, suggesting distinct metabolic signatures for each subtype.

Conclusion

Our study indicated a significant perturbation in oxylipin metabolism among patients with PHO, with distinct metabolic signatures observed between PHOAR1 and PHOAR2. The disruption extended beyond the metabolism of PGE2. It encompassed a broader alteration across the polyunsaturated fatty acid metabolism spectrum, including various eicosanoids and oxylipins. Our work provided a comprehensive understanding of the pathogenesis of PHO, and underscored the potential for subtype-specific therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetabolomicsOsteoarthropathy, Primary HypertrophicOxylipinsHumansFemaleMaleAdultDinoprostoneMiddle AgedCase-Control StudiesYoung AdultBiomarkersTandem Mass SpectrometryEicosanoids

Stichwörter der Autor:innen

oxylipinsprimary hypertrophic osteoarthropathyprostaglandin E2targeted metabolomics

Substanzen

DinoprostoneOxylipinsBiomarkersEicosanoids

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology, National Commission of Health, State Key Laboratory for Complex, Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical…
  • Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100…

ORCID-Profile: Ou Wang, Mei Li, Yan Jiang, Yiyi Gong, Weibo Xia

Förderung

  • National Key R&D Program of China
  • Beijing Municipal Natural Science Foundation
  • National Natural Science Fund
  • CAMS Innovation Fund for Medical Sciences
  • National High Level Hospital Clinical Research Funding
  • Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences

Zitieren

APA

Pang, Q., Qi, X., Chi, Y., Jiajue, R., Zhang, L., Cui, L., Wang, O., Li, M., Xing, X., Jiang, Y., Gong, Y., & Xia, W. (2025). Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis. The Journal of Clinical Endocrinology & Metabolism, 110(8), e2591-e2604. https://doi.org/10.1210/clinem/dgae737

Vancouver

Pang Q, Qi X, Chi Y, Jiajue R, Zhang L, Cui L, et al. Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis. The Journal of Clinical Endocrinology & Metabolism. 2025;110(8):e2591-e2604. doi:10.1210/clinem/dgae737

BibTeX
@article{Pang2025,
  author = {Pang, Qianqian and Qi, Xuan and Chi, Yue and Jiajue, Ruizhi and Zhang, Li and Cui, Lijia and Wang, Ou and Li, Mei and Xing, Xiaoping and Jiang, Yan and Gong, Yiyi and Xia, Weibo},
  title = {Targeting Metabolomics in Primary Hypertrophic Osteoarthropathy: Uncovering Novel Insights into Disease Pathogenesis},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {8},
  pages = {e2591--e2604},
  doi = {10.1210/clinem/dgae737}
}
Kostenlos starten →